Home » Prescriptions for Merck’s Singulair Plunge After Loss of U.S. Patent
Prescriptions for Merck’s Singulair Plunge After Loss of U.S. Patent
Weekly prescriptions for Merck’s asthma and allergy treatment Singulair (montelukast) plunged nearly 90 percent within four weeks of the August introduction of competing generic copies.
NASDAQ
NASDAQ
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May